Phanstiel S. Louise
Phanstiel S. Louise's purchase track record
Phanstiel S. Louise has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/14/2026 | BFLY | $1000K | pending | pending | — |
| 2/25/2026 | MYGN | $495K | -17.8% | -34.7% | +10.5% |
| 12/15/2025 | BFLY | $571K | +21.4% | +74.8% | +10.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.
Transaction History
| BFLY | ▲ Buy | Open Market | 115,200 | $1000K | 8/14/2026 | View on chart |
| BFLY | ▲ Buy | Grant | 25,447 | $0 | 6/22/2026 | View on chart |
| MYGN | ▲ Buy | Grant | 59,701 | $0 | 6/4/2026 | View on chart |
| MYGN | ▲ Buy | Open Market | 48,000 | $224K | 2/27/2026 | View on chart |
| MYGN | ▲ Buy | Open Market | 50,407 | $242K | 2/26/2026 | View on chart |
| MYGN | ▲ Buy | Open Market | 6,100 | $29K | 2/25/2026 | View on chart |
| BFLY | ▲ Buy | Open Market | 185,261 | $571K | 12/15/2025 | View on chart |
| BFLY | ▲ Buy | Grant | 80,434 | $0 | 6/13/2025 | View on chart |
| MYGN | ▲ Buy | Grant | 49,796 | $0 | 6/5/2025 | View on chart |
| BFLY | ▼ Sell | Open Market | 60,049 | $118K | 9/13/2024 | View on chart |
| BFLY | ▲ Buy | Grant | 157,894 | $0 | 6/10/2024 | View on chart |
| MYGN | ▲ Buy | Grant | 15,695 | $0 | 6/6/2024 | View on chart |
| BFLY | ▲ Buy | Grant | 65,789 | $0 | 6/20/2023 | View on chart |
| MYGN | ▲ Buy | Grant | 15,151 | $0 | 6/1/2023 | View on chart |
| BFLY | ▲ Buy | Grant | 48,231 | $0 | 6/17/2022 | View on chart |
| MYGN | ▲ Buy | Grant | 17,275 | $0 | 6/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Butterfly Network Announces Long‑Term Alliance with VCOM and Gains New Coverage
Butterfly Network entered a long‑term partnership with the Edward Via College of Osteopathic Medicine to develop a new ultrasound education model. The collaboration aims to expand training tools for medical students. In addition, Canaccord Genuity started coverage on the stock, setting a price target of $10. The move reflects growing interest in Butterfly’s technology and its educational applications.
Butterfly Network Announces Long‑Term Alliance with VCOM and Gains New Coverage. Butterfly Network entered a long‑term partnership with the Edward Via College of Osteopathic Medicine to develop a new ultrasound education model. The collaboration aims to expand training tools for medical students. In addition, Canaccord Genuity started coverage on the stock, setting a price target of $10. The move reflects growing interest in Butterfly’s technology and its educational applications.